<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215071</url>
  </required_header>
  <id_info>
    <org_study_id>AB 25/02</org_study_id>
    <nct_id>NCT01215071</nct_id>
  </id_info>
  <brief_title>Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA</brief_title>
  <official_title>Prospektiv Randomisierte Studie Zum Vergleich Einer Ausgedehnten Mit Einer eingeschränkten Pelvinen Lymphadenektomie Bei Der Operativen Therapie Des Harnblasenkarzinoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Urologic Oncology (AUO)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association of Urologic Oncology (AUO)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the therapeutic benefit of extended versus limited lymphadenectomy at
      the time of radical cystectomy in patients with bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The extent of pelvic lymphadenectomy in the surgical treatment of muscle-invasive, clinically
      locally bladder cancer is not yet standardized. There are no data from randomized,
      prospective studies on the prognostic role of regional lymphadenectomy.

      Results of retrospective studies suggest, that the prognosis of patients with muscle-invasive
      bladder cancer can be improved by extending the limits of pelvic lymphadenectomy. Furthermore
      it could be demonstrated in a prospective study that the pattern of metastasis of bladder
      cancer has a high variability. About two-thirds of lymph node metastases are found outside
      the normally cleared areas of lymphadenectomy. In this study patients will be randomized into
      arms with limited versus extended lymphadenectomy.

      The limited lymphadenectomy includes the removal of the obturatoric, external and internal
      iliac lymph nodes, the extended one includes the removal of all lymph nodes between pelvic
      floor and the inferior mesenteric artery. The primary objective of the study is to detemine
      the influence of limited versus extended lyphadenectomy at the time of radical cystectomy on
      recurrence-free survival. Secondary study objectives include the influence on cancer-specific
      survival, overall survival, complication rates, histopathologic N-stage, the localization of
      recurrence and influence of adjuvant chemotherapy . Adjuvant chemotherapy is optional and is
      recommended in patients with locally advanced disease (pT3/4) or regional lymph node
      metastasis (pN+).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free Survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Definition Recurrence-free survival: Time from radical cystectomy to tumor reccurence or death from any cause up to 5 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival (CSS)</measure>
    <time_frame>5 years</time_frame>
    <description>Definition Cancer-specific suvival: Time from radical cystectomy to death from bladder cancer up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Definition Overall survival: Time from radical cystectomy to death from any cause up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of type and location of tumour progression(local recurrences and distant metastases)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on histopathological stage (Will Rogers phenomenon)</measure>
    <time_frame>5 years</time_frame>
    <description>Definition Effect on histopathologic stage: Influence of extended lymphadenectomy on detection of lymph node metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of adjuvant chemotherapy (by subgroup analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of complications</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>limited lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fields 5, 7, 9, 11, 13, 14 are removed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>extended lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>limited lymphadenectomy</intervention_name>
    <description>Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)</description>
    <arm_group_label>limited lymphadenectomy</arm_group_label>
    <other_name>eingeschränkte Lymphadenektomie</other_name>
    <other_name>eingeschränkte LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>extended lymphadenectomy</intervention_name>
    <description>Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)</description>
    <arm_group_label>extended lymphadenectomy</arm_group_label>
    <other_name>ausgedehnte Lymphadenektomie</other_name>
    <other_name>ausgedehnte LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven, invasive urothelial bladder cancer, locally completely
             resectable (T1G3 - T4a, Nx)

          -  Age &gt;= 18 years

          -  Written consent of the patient

          -  Patient compliance and geographic proximity to allow adequate follow-up

        Exclusion Criteria:

          -  Histologically or by imaging diagnostics proven organ metastases

          -  Radiographic evidence of enlarged lymph nodes (&gt; 1 cm) above the aortic bifurcation in
             conjunction with pelvic lymph node metastases

          -  Radiographic or other evidence of T4b-tumor (infiltration of the pelvic wall or other
             organ systems)

          -  Prior neoadjuvant chemotherapy of bladder cancer

          -  Prior previous pelvic lymphadenectomy

          -  Prior radiotherapy to the pelvis

          -  internal medical or anesthetic risk factors that require a short operation time

          -  Palliative cystectomy (f.e. bulky-disease, infiltration of adjacent structures)

          -  Evidence of another tumor restricting life expectancy of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen E. Gschwend, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUO - Association of Urologic Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological hospital, Städt. Kliniken Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine University</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of urology, städt. Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Hospital Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Holweide</name>
      <address>
        <city>Köln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto von Guericke University</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum r. d. Isar der TUM</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls University</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological hospital, University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.auo-online.de</url>
    <description>The AUO Homepage where this study is presented</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphadenectomy</keyword>
  <keyword>Extension</keyword>
  <keyword>Bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

